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Availabl online 22 January 2015Abstract Identification of pivotal factors potentially present in the in situ environment and capable of influencing the function
of CD34+ cells, which can be used for autologous cell therapy, is of paramount interest. SHh is one of the morphogens essential for
embryonic vascular development as well as postnatal neovascularization, and the activation of SHh signaling with angiogenic and
vascular differentiation responses in CD34+ cells by SHh treatment differed depending on the G-CSF treatment or the background
disease. SHh enhanced the migration, proliferation, adhesion, and EPC colony forming capacities of G-CSF mobilized CD34+ cells,
increasing the vasculogenic/angiogenic potential for neovascularization. An increase in the differentiation potential of CD34+ cells
toward vascular lineages was demonstrated with SHh treatment involving TGFβ signaling pathway. The SHh-activated G-CSF
mobilized CD34+ cells directly contributed to vascular regeneration while non-activated CD34+ cells showed a lower regenerative
capacity in a mouse ischemic hindlimbmodel. SHh signaling regulates human CD34+ cell fate and function, and may potentiate the
therapeutic effect of G-CSF mobilized CD34+ cells on ischemic diseases.
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166 K. Kanaya et al.Introduction (BM)-derived CD34+ cells for vascular regeneration in theHedgehog (Hh) proteins are crucial regulators of organ
development during embryogenesis. Sonic Hedgehog (SHh) is a
prototypical morphogen known to regulate epithelial/mesen-
chymal interactions during embryonic development of limbs,
lung, gut, hair follicles, and bone (Johnson and Tabin, 1997;
St-Jacques et al., 1998, 1999). Patched (PTCH) and Smoothend
(SMO) are known receptors of SHh, and PTCH inhibits SMO
activation of the downstream Gli family transcription factors,
which results in the activation of target genes (Bhardwaj et al.,
2001; Cohen, 2003). Several recent observations have sug-
gested an involvement of SHh in postnatal neovascularization
(Kanda et al., 2003; Kusano et al., 2004, 2005; Mackie et al.,
2012; Renault et al., 2010). In addition, exogenous administra-
tion of SHh has been shown to induce angiogenesis and
accelerate repair of the ischemic myocardium and skeletal
muscle (Kusano et al., 2004; Pola et al., 2003). Other reports
also demonstrated that SHh gene therapy could significantly
accelerate wound healing by inducing arteriogenesis (Asai et
al., 2006) or restore nerve function in diabetic neuropathy by
promoting angiogenesis (Kusano et al., 2004).
Yamazaki et al. showed that PTCH receptor expression
was observed in cultured human peripheral blood-derived
endothelial progenitor cells (EPCs) but not in mature
endothelial cells (Yamazaki et al., 2008), suggesting that
SHh might have a certain effect on human EPCs and CD34+
cells. Indeed, recent studies demonstrated that a combined
therapy of SHh gene transfer and mouse cultured EPC
transplantation enhanced angiogenesis in ischemic skeletal
muscle (Palladino et al., 2012) and that genetically modified
human CD34+ cells with SHh preserved cardiac function
increasing angiogenesis in the ischemic myocardium follow-
ing myocardial infarction (Mackie et al., 2012). Based on
these evidences, we hypothesized that activation of the SHh
pathway during development might regulate the fate of
human EPCs, CD34+ cells, and promote vasculogenic activities
in ischemic tissues in situ.
CD34 has been recognized as one of the
best-characterized human hematopoietic stem cell-related
cell surface antigens defined to date (Sutherland et al.,
1993). Its expression is down-regulated during hematopoi-
etic development and it is not found on mature peripheral
blood cells. In fact, the function of CD34 was reported to be
an adhesion molecule that allows stem cells to remain in the
proper stromal environment for hematopoiesis in the bone
marrow (Gordon et al., 1987), and transplantation of bone
marrow- or cord blood-derived CD34+ cells was shown to
reconstitute ablated bone marrow following lethal irradia-
tion as part of therapeutic approaches aiming for the cure of
hematological disorders involving leukemia (Link et al.,
1996), malignant lymphoma (Tomblyn et al., 2007), and
refractory anemia (Korbling et al., 1995). On the other hand,
putative endothelial cell (EC) progenitors or angioblasts
were isolated from adult human peripheral blood for the
first time by selection on the basis of expression of the cell
surface antigen CD34+ and recognized as EPCs in 1997
(Asahara et al., 1997). Since then, a number of preclinical
animal studies (Iwasaki et al., 2006; Jujo et al., 2010; Wang
et al., 2010) and clinical studies (Kawamoto et al., 2009;
Manginas et al., 2007) have indicated the therapeutic
potential of EPCs including peripheral or bone marrowischemic limb or ischemic heart disease. The several lines of
evidences accumulated in these studies clearly supported
the therapeutic efficacy of CD34+ cell transplantation in
ischemic tissues, however, a clear and distinct mechanism of
action for the direct or indirect CD34+ cell contribution to
neovascularization remains to be established.
Previous studies identified concurrent dose-dependent
effects of CD34+cells on the incorporation into vascular
endothelial cells and the vascular recovery of ischemic
tissues following transplantations (Iwasaki et al., 2006).
However, other studies have demonstrated that the major
positive effect of CD34+ cell transplantation on vascular
regeneration in ischemic tissues was due to the production
of various stem/progenitor chemokines, angiogenesis-related
cytokines, angiogenic growth factors, anti-inflammatory cyto-
kines, and survival factor, promoting resident EC proliferation
and migration (Ii et al., 2005). We and others have experienced
difficulties in regard to the commitment of CD34+ cells into
totally differentiated endothelial cells in vitro. Several publi-
cations also questioned the involvement of EPCs in new blood
vessel formation during tumor angiogenesis or in ischemic
diseases, by showing perivascular lodging cell void of endothe-
lial lineage profiles but expressing smooth muscle cell lineage
markers (Rajantie et al., 2004).
A possible unifying explanation for these diverse and to
some extent controversial aspects of EPC biology may be the
current lack of knowledge about the pivotal factors present
in the in situ environments of EPCs, depending on as well as
influencing the molecular make-up and interactions of the
transplanted cells with the recipient tissues, and being thus
possibly involved in the induction and specification of the
cell fate and regenerative function of EPCs and CD34+ cells in
ischemic tissues. We hypothesize that SHh may be one of
these pivotal players present in situ and possibly involved in
the regulation of the fate of EPCs, promoting the differen-
tiation of CD34+ cells and EPCs into regenerative vascular
cells under ischemic conditions. To evaluate the possible
effects of SHh on CD34+ derived EPCs, we designed and
performed a series of in vitro and in vivo experiments.
Methods
Human recombinant Sonic Hedgehog (SHh) protein
Human recombinant SHh protein, N-terminus (Cat #: 1314-SH-
025) was purchased from R&D Systems, Inc. (MN). Human SHh
cDNA encodes a 45 kDa precursor protein. An autocatalytic
reaction yields a 19 kDa amino-terminal domain SHh-N protein
containing cholesterol and palmitate, and a 25 kDa carboxy-
terminal domain SHh-C protein. The N-terminal domain retains
all known signaling capabilities, while the C-terminal
domain is responsible for the intramolecular processing,
acting as a cholesterol transferase. SHh can act as both a
short-range contact dependent factor and as a long-range,
diffusible morphogen.
Cells
G-CSF mobilized human peripheral blood CD34+ cells were
purchased from ALL CELLS (Emeryville, CA) and used for
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“Hv-GmCD34”. We also used G-CSF mobilized human
peripheral blood CD34+ cells collected from patients with
Burger's disease who enrolled in a clinical trial regarding
intramuscular transplantation of autologous and G-CSF-
mobilized CD34+ cells in patients with intractable critical
limb ischemia (CLI) in Institute for Biomedical Research and
Innovation (IRBI, Kobe, Japan) (Pt-GmCD34) and fresh
human peripheral blood CD34+ cells were isolated from
healthy volunteers (Hv-CD34) and diabetic volunteers for in
vitro experiments. This cell collection was performed in
accordance with an approval of institutional ethical com-
mittee of IRBI. All cells were kept in cryopreservation until
the experiments were performed. Cells were thawed and
incubated in 5% FBS/EBM2 supplemented with growth
factors (EGM2-MV BulletKit, Lonza) for 24 h for recovery of
cell activity. Cells were further incubated with SHh protein
at following doses: 0, 0.2, 1.0 and 5.0 μg/mL for 24 h under
a hypoxic condition (37 °C in 5% O2 and 5% CO2). The cells
pre-treated with SHh were used for in vitro and in vivo
experiments.Cell transplantation in a hindlimb ischemia model
Athymic nude mice (age 8–10 week and weighting 17–22 g)
were used for all experiments. Mice underwent surgery toFigure 1 SHh signaling-related gene expressions in SHh-
treated human CD34+ cells. Human CD34+ cells isolated from
healthy volunteer with (A, Hv-GmCD34) or without G-CSF
administration (C, Hv-CD34) and patient of Burger's disease
with G-CSF administration (B, Pt-GmCD34). The mRNA expres-
sions of SHh, PTCH1, PTCH2, SMO, and GLI1 were examined in
each type of cells treated with the indicated concentrations of
SHh protein following 24 h in culture by real-time RT-PCR. The
relative mRNA expression levels of the target genes were
normalized to those of GAPDH and the representative data are
presented following the triplicated analyses.induce severe unilateral hindlimb ischemia. The animals
were anesthetized by intraperitoneal injection of Nembutal™
(pentobarbital, 10 mg/kg) (Sigma-Aldrich, Tokyo, Japan)
followed by subcutaneous injection of buprenorphine
(0.05 mg/kg/day) for 3 days after surgery. Under sufficient
anesthesia, the left iliac artery and vein, the deep femoral
and circumflex arteries and veins, and the entire left
superficial artery and veins (from just below the deep
femoral arteries to the popliteal artery and vein) were
ligated and cut. CD34+ cells were pre-incubated with SHh
(1 μg/mL) in 5% FBS/EBM2 supplemented with growth
factors (EGM2-MV BulletKit, Lonza) for 24 h under a hypoxic
condition (37 °C in 5% O2 and 5% CO2). The SHh-treated
CD34+ cells (1 × 105 cells) were locally injected to lower
limb muscles dividing into 4 sites. All surgical procedure
was approved by RIKEN institutional animal use and care
committee (Animal protocol #: AH16-06-17).Statistical analysis
All values are presented as mean ± SEM. Statistical com-
parisons between 2 groups were performed by Student t
test. Multiple groups were analyzed by one-way ANOVA
followed by appropriate post hoc test (Tukey procedure) to
determine statistical significance. All in vitro experiments
were repeated at least in triplicate and analyzed. The authors
had full access to the data and take full responsibility for its
integrity. All authors have read and agree to themanuscript as
written.
The other methods are described in detail in Supplemen-
tary material.Results
SHh activates SHh signaling in G-CSF mobilized (Gm)
CD34+ cells
We first performed a series of pilot experiments for the
selection of a suitable cell type in this study. We screened
for SHh signaling among Gm-CD34+ cells obtained from a
healthy volunteer (male, 42 y.o.) (Hv-GmCD CD34+ cells),
Gm-CD34+ cells obtained from a patient with inflammatory
vascular disease (male, 39 y.o., Burger disease) (Pt-GmCD
CD34+ cells), and non-GmCD34+ cells obtained from a
healthy volunteer (male, 44 y.o.) (Hv-CD34+ cells) by
quantitative real-time PCR (qPCR) analysis. SHh signaling
was already activated with SHh, PTCH1, and GLI1 mRNA
upregulations in Hv-CD34+ cells (0 μg/mL in Fig. 1C), while
little activation of SHh signaling was observed in Hv-Gm
CD34+ cells and Pt-Gm CD34+ cells with only high SMO and
low GLI1 mRNA expressions. Interestingly, no PTCH1 mRNA
expression was detected in both Hv-Gm CD34+ cells and
Pt-Gm CD34+ cells, and PTCH2 mRNA expression was
detected only in Hv-Gm CD34+ cells (0 μg/mL in Fig. 1A
and B), suggesting that PTCH2 but not PTCH1 may play a role
as a receptor for SHh in HV-GmCD34+ cells. The SHh
treatment induced no mRNA expressions of SHh and GLI1 at
any dose of SHh in Hv-CD34+ cells, in contrast, SHh and GLI1
mRNA expressions were upregulated by SHh (1 μg/mL)
treatment in Hv-GmCD34+ cells and Pt-Gm CD34+ cells
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SHh stimulation in Gm CD34+ cells.
In the regulation of angiogenic/vasculogenic growth
factors by SHh, the treatment with SHh upregulated
VEGF-A mRNA expression regardless of the cell sources
(Fig. 2A, B, and C) and VEGF-B and PDGF-A mRNA expressions
in Pt-GmCD34+ cells and Hv-CD34+ cells (Fig. 2A and B). The
ANG1 mRNA expression was upregulated by SHh (1 μg/mL)
only in Pt-GmCD34+ cells (Fig. 2B), and SHh did not affect
the mRNA expressions of PDGF-B and HGF in all cell types.
For the assessment of vascular differentiation of CD34+ cells
by SHh, CD31 mRNA was highly expressed only in GmCD34+
cells (Fig. 2D and E), while not only CD31 but also eNOS,
calponin, and SM α-actin (α-SMA) were slightly expressed or
not expressed at all in all type of cells (Fig. 2D, E, and F).
Although SHh treatment exhibited a little effect on CD31
mRNA expression, SHh upregulated eNOS and αSMA in
GmCD34+ cells (Fig. 2E and F) and did eNOS, calponin, and
αSMA in non-GMCD34+ cells (Fig. 2F). Similar gene expression
patterns in response to SHh treatment were observed in
other individuals (n = 2) in each group (data not shown).
Thus, we decided to use Hv-GmCD34+ cells rather than
Pt-GmCD34+ cells in the following series of pilot experiments
for the reasons of; 1) SHh signaling activation in response to
exogenous SHh treatment with PTCH2 receptor, 2) insuffi-
cient number of cells with the same lot/person for all
experiments in this study, and 3) unevenness depending on
the background diseases in the patients' cells compared with
the healthy volunteers' cells.Figure 2 Angiogenic growth factor and vascular cell-related
gene expression levels in SHh-treated human CD34+ cells. Human
CD34+ cells isolated from healthy volunteer with (A and D,
Hv-GmCD34) or without G-CSF administration (C and F, Hv-CD34)
and patient of Burger's diseasewith G-CSF administration (B and E,
Pt-GmCD34). The mRNA expressions of growth factor, VEGF-A,
VEGF-B, angiopoietin 1 (ANG1), PDGF-A, PDGF-B, and hepatocyte
growth factor (HGF) and vascular gene, CD31, eNOS, calponin,
and smooth muscle α-actin (aSMA) were examined in each type of
cells treated with the indicated concentrations of SHh protein
following 24 h in culture by real-time RT-PCR. The relative mRNA
expression levels of the target genes were normalized to those of
GAPDH and the representative data are presented following the
triplicated analyses.SHh promotes CD34+ cell functional activities
To elucidate the direct effects of SHh on Hv-GmCD34+ cells,
we performed a series of in vitro assays. The proliferation
activity of the SHh-treated CD34+ cells was examined. SHh
significantly increased proliferation activity in a dose
dependent manner (Fig. 3A). To assess the CD34+ cell
adhesion activity, the cells were incubated with SHh in
fibronectin-coated culture dishes for 48 h. The number of
adhered CD34+ cells was significantly increased in a dose
dependent manner (Fig. 3B). Next, we evaluated the effect
of SHh on CD34+ cell migration. The migratory response of
CD34+ cells toward different concentrations of SHh was
assessed by modified Boyden's chamber assay. The effect of
SHh on CD34+ cell migration peaked at 1 μg/mL while a
higher concentration of 5 μg/mL resulted in less effect
(Fig. 3C). Finally, EPC colony forming assay (Masuda et al.,
2012) with CD34+ cells was performed to evaluate in vitro
angiogenic activity. SHh significantly increased the forma-
tion of total colonies including small type and large type
(Supplemental Fig. 1S-A) with CD34+ cells at a dose of 1 μg/mL
but not of 5.0 μg/mL (Fig. 3D). CD34+ cells with large colony
forming capacity represent high angiogenic capacity com-
pared to those with small colony forming capacity (Masuda et
al., 2012). Even though the colony forming EPCs are in a minor
population, they will be distributed in neovasculature pro-
ducing a variety of growth factors/cytokines that can promote
angiogenesis with resident endothelial cells. The paracrine
effect is amajor function of CD34+ cells. Interestingly, the EPC
colony forming capacity of CD34+ cells isolated from volun-
teers with diabetes (DM) was lower than that with healthyvolunteers (non-DM) (Supplemental Fig. 1S-B and -C). SHh
treatment (1 μg/mL) significantly increased the number of
large EPC colonies in non-DM group (Supplemental Fig. 1S-B)
Figure 3 The promotional effect of SHh on functional activities of human G-CSF mobilized CD34+ cells. A, The proliferation activity
of CD34+ cells was expressed as optical density (OD) measured at 650-nm wavelength with MTS dye. (n = 6) B, the adhesion activity of
CD34+ cells was expressed as the number of attached cells on fibronectin coated plastic dishes after 48 h in culture. (n = 3) C, the
SHh-treated or non-treated CD34+ cell migration was induced by SDF-1α (100 ng/mL), the number of migrated cells was evaluated as
the migration activity after 48 h in culture. D, EPC-Colony forming assay (n = 3). The colony forming activity was expressed as the
number of SHh-treated or non-treated CD34+ cell-derived colonies in methylcellulose-based special medium after 18 days in culture.
E, Vasculogenesis assay with HUVECs and SHh-treated CD34+ cells. The DiI (red fluorescence)-labeled SHh-treated or non-treated
CD34+ cells and HUVECs were cultured for 24 h on Matrigel™ coated chamber slides. The DiI-labeled CD34+ cells co-localized with
cord-like structures formed by HUVECs were visualized under a phase contrast/fluorescent microscope. (E) Black arrows indicate
incorporated CD34+ cells. Square boxes indicate high magnification of selected area. F, Quantification of incorporated CD34+ cells
into cord-like structures of HUVECs. The vasculogenic activity of CD34+ cells was assessed by the frequency of CD34+ cell
incorporation into cord-like structures. *P b 0.05; **P b 0.001; and ***P b 0.0001 vs. 0 μg/mL of SHh.
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Fig. 1S-C), suggesting that background disease such as DM
influences the response of CD34+ cell function to SHh
treatment.
Finally, in order to examine whether SHh promotes
incorporation of CD34+ cells into cord-like structures made of
HUVECs, tube formation assay was performed by co-culturing
DiI-labeled CD34+ cells with HUVECs on Matrigel. The CD34+
cells co-localized with the formed cord-like structures of
HUVECs andwere visualized under a phase contrast/fluorescent
microscope (Fig. 3E). The number of incorporated CD34+ cells
(red) into the cord-like structurewas significantly greater in the
SHh-treated group at doses of 0.2 and 1.0 μg/mL than that in
the control group, however, high dose of SHh (5.0 μg/mL)
showed no effect (Fig. 3F), suggesting that SHh increased
the vasculogenic or pro-angiogenic activity of CD34+ cells at
a low/mid concentration but not at a high (5.0 μg/mL)
concentration.
CD34+ cells show differentiation potential into
endothelial and smooth muscle lineages by SHh
To confirm the differentiation potential of CD34+ cells into the
endothelial and smooth muscle lineages by SHh treatment,protein expressions of CD31 and eNOS for EC differentiation and
calponin and SMα-actin for VSMC differentiationwere examined
by fluorescent immunocytostaining. SHh significantly increased
calponin and SMα-actin positivity in CD34+ cells under SMC
differentiation culture condition (Fig. 4A and C). On the other
hand, although there was no significant change in CD31
positivity with SHh versus without SHh in CD34+ cells, eNOS
positivity was significantly increased in CD34+ cells by SHh under
EC differentiation culture condition (Fig. 4B and D). These
findings suggest that SHh can promote CD34+ cell differentiation
into the endothelial lineage and vascular smoothmuscle lineage
under specific cell differentiation conditions.
TGFβ signaling pathway may be involved in SHh-
induced CD34+ cell fate in vascular differentiation
To explore the mechanism for which SHh promoted
vascular geneupregulation in CD34+ cells, we examined a
series of signaling molecule gene expressions with SHh
treatment focusing on TGFβ/BMP signaling pathway by
qPCR analysis (Table 1S). SHh (1.0 μg/mL) upregulated
mRNA expressions of not only TGFβ1 and its receptor
TGFβR2 but also the downstreammolecules of TGFβ signaling
pathway, AlK5, Smad2, Smad3, and Smad4. In contrast, little
Figure 4 Immunocytochemistry for vascular protein expressions in human G-CSF mobilized CD34+ cells with or without SHh
treatment. The protein expressions of, calponin/SMα-actin (VSMC marker) (A) and eNOS/CD31 (EC marker) (B) were examined in
CD34+ cells with or without SHh treatment (1.0 μg/mL) following 14 days in culture under VSMC differentiation condition and EC
differentiation condition, respectively. Arrows indicate each staining (red, calponin and eNOS, green, SMα-actin and CD31)-positive
cells. The percent of staining-positive cells was calculated and averaged (C and D). ns, not significant, *P b 0.05 and **P b 0.001 vs. 0 μg/mL
of SHh.
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the downstream molecules of TGFβ/BMP signaling pathway
ALK1, Smad1, and Smad5 were observed (Fig. 5A and
Supplemental Fig. 2S). Consistent with themRNA upregulation
of TGFβ signaling pathway, mRNA expressions of a number of
vascular transcription factors, Ets2, Fli1, TEL, SCL, Sp1,
Runx1, CBF1, ZEB2, and Id2 were also upregulated in a quite
similar dose response manner of SHh (Fig. 5B). The SHh-
induced protein upregulations of keymolecule, TGFBR2, Smad
3, and Smad 4 were further confirmed by Western blotting
(Supplemental Fig. 3S). These results allowed us to speculate
that SHh-induced vascular differentiation ismediated by TGFβ
signaling pathway rather than BMP signaling pathway in CD34+
cells.
We next performed a TGFβ blocking study to test whether
the TGFβ signaling pathway is critical for SHh-induced
vascular differentiation and growth factor production in
CD34+ cells. Although the upregulated CD31 gene expression
by SHh was not canceled by TGFβ inhibitor (SB525334)
significantly, other vascular marker genes of eNOS, calponin,
SM alpha actin (aSMA), and growth factor VEGF-A were
significantly reduced by TGFβ signaling inhibition (Fig. 5C),suggesting that TGFβ signaling is, at least in part, involved in
SHh-induced vascular differentiation and VEGF-A production
in CD34+ cells.SHh promotes the effect of CD34+ cells on blood
perfusion recovery following HLI
Based on the results in vitro, we have tested the hypothesis
that SHh might enhance the effect of CD34+ cells on blood
perfusion recovery in ischemic hindlimbs. We transplanted
human peripheral blood-derived CD34+ cells with or without
SHh-pretreatment via intramuscular injection, and PBS instead
of cells was used as a control.
Serial measurements of blood perfusion in hindlimbs by
LDPI were performed at days 0, 7, 14, 21, and 28. LDPI
disclosed striking differences in blood perfusion on and after
day 14 post-induction of HLI (Fig. 6A). The blood perfusion
ratio of ischemic/non-ischemic hindlimbs in the SHh-CD34+
group significantly increased compared with the control
group, while the CD34+ group did not show a significant
increase of the blood perfusion ratio after 14 days post-HLI
Figure 5 TGFβ-Smad/BMP-Smad signaling-related gene and vascular gene expressions in SHh-treated human G-CSF mobilized
CD34+ cells. The mRNA expressions of TGFβ1/BMP2, downstream molecule of TGFβ/BMP including the receptors, (A) vascular
transcription factor, (B) and vascular genes (C) were examined in CD34+ cells treated with the indicated concentrations of SHh
protein in the presence or absence of TGFb antagonist SB525334 (5 μM) following 24 h in culture by real-time RT-PCR. The relative
mRNA expression levels of the target genes were normalized to those of GAPDH and the representative data are presented following
the triplicated analyses (n = 3 in each group, *P b 0.05; **P b 0.01; ***P b 0.001, ****P b 0.0001). Ets2: v-ets avian erythroblastosis
virus E26 oncogene homolog 2, Fli1: Friend leukemia virus integration 1, TEL: Ets variant 6, SCL: stem cell leukemia, Sp1: specificity
protein 1, Runx1: Runt-related transcription factor 1, CBF1: CRT/DRE binding factor 1, ZEB2: Zinc finger E-box binding homeobox 2,
Id2: inhibitor of DNA binding 2, dominant negative helix-loop-helix protein.
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increase of the blood perfusion ratio of ischemic/non-ischemic
hindlimb compared with the CD34+ group at 21 days post-HLI
surgery (Fig. 6B). Although the endogenous mouse tissue-
derived SHh mRNA expression was upregulated 3 days follow-
ing HLI (Fig. 6C), the low expression levels and the delay of
expression timing may exhibit less effect on transplanted
CD34+ cells. These findings suggest that pre-treatment of SHh
promoted the angiogenic/vasculogenic activity of CD34+ cells
in ischemic hindlimbs resulting in significant blood perfusion
recovery.SHhpromotes the effect of CD34+ cells on angiogenesis
and vasculogenesis in ischemic hindlimb
To provide histological evidence of improved blood perfusion in
ischemic hindlimbs by SHh treated CD34+ cell transplantation,histological assessment of capillaries in the ischemic muscle
was performed. The staining with the EC markers isolectin
B4 and Ulex lectin was performed on skeletal muscle
sections retrieved from ischemic hindlimbs after HLI surgery
to quantify capillary density as an index of neovasculariza-
tion (Fig. 7A). The SHh-CD34+ group exhibited significantly
increased capillary density compared with the control
group, whereas the CD34+ group did not on day 14 and day
28 after HLI surgery. Only on day 14 after surgery, there was
a significant difference between the SHh-CD34+ group and
the CD34+ group (Fig. 7B).
To confirm whether the transplanted CD34+ cells incorpo-
rated into vascular structures in the ischemic limbmuscles, we
performed double-immunofluorescent staining of human
mitochondria (hMtCd)/lectin (Fig. 7C) and hMtCd/SMα-actin
(Fig. 7D). Double-positive cells of hMtCd/lectin and hMtCd/
SMα-actin were more frequently observed in the SHh-CD34+
group than the CD34+ group. However, the frequency of
Figure 6 Blood perfusion recovery in ischemic hindlimbs transplanted with SHh-treated human G-CSF mobilized CD34+ cells.
A, Representative blood perfusion images assessed by Laser-Doppler perfusion imaging system immediate, 7, 14, 21, and 28 days
following hindlimb ischemia treated with PBS (Control), CD34+ cells (CD34), and SHh-treated CD34+ cells (CD34 + SHh). Purple/blue,
low blood perfusion; green/yellow, mid blood perfusion; and red/orange, high blood perfusion. Arrows indicate ischemic hindlimbs
with each treatment. B, Quantification of blood perfusion in ischemic hindlimbs. The relative blood perfusion ratio of ischemic limb
(left) to intact limb (right) was calculated and averaged in each group. (n = 8 in each group) C, SHh gene expression in mouse muscle
tissue with (HLI+) or without HLI (HLI−). SHh mRNA expressions in hindlimb were analyzed by real-time RT-PCR 3 days following
surgery, and the expressions were normalized to GAPDH (n = 4). ns, not significant; *P b 0.05; and ****P b 0.0001 vs. control.
172 K. Kanaya et al.hMtCd/SMα-actin positive cells was lower than that of hMtCd/
lectin positive cells. Indeed, the perimeters of both hMtCd+/
Lectin+ and hMtCd+/SMα-actin+ were significantly greater inFigure 7 Histological assessment of vascularity in ischemic hindlim
cells. A, Fluorescent immunostaining with FITC-isolectin B4 for det
sections in each group 2 weeks and 4 weeks after surgery and trea
CD34+ cells (CD34 + SHh). B, Quantification of vascularity in ische
counting capillaries stained in green (A) in high power field (HPF) a
*P b 0.01 vs. CD34 and **P b 0.001 vs. control. (n = 6 in each grou
(hMtCd, red) and Lectin (C) or SM α-actin (green) (D) was perform
(CD34 + SHh) transplanted ischemic hindlimb muscles 2 weeks aft
hMtCd+ cells (red) and Lectin+ capillaries (green) or SM α-actin+ arter
hindlimb muscle. Quantification of hMtCd+/Lectin+ perimeter (length
tissue. Six sections from 3 mice were examined by morphometry and
immunostaining for transplanted SHh-treated CD34+ cells vs. non-tre
were visualized with an antibody for human mitochondria (hMtCad) in
(CD34+ cells) and arrows (SHh-treated CD34+ cells) indicate double pthe SHh-CD34+ group than that in the CD34+ group (Fig. 7E and
F, respectively). Finally, we examined the VEGF-A protein
expression of one of the upregulated genes by SHh (1.0 μg/mL)b muscles transplanted with SHh-treated G-CSF mobilized CD34+
ection of capillaries (green) was performed on ischemic muscle
tment with PBS (Control), CD34+ cells (CD34), and SHh-treated
mic hindlimb muscles. The capillary density was calculated by
nd averaged in each group 2 weeks and 4 weeks after surgery.
p) double fluorescent immunostaining for human mitochondria
ed on sections of CD34+ cell (CD34) and SHh-treated CD34+ cell
er surgery. Merged images indicate co-localization (arrows) of
ioles (green) in the SHh-treated CD34+ cell transplanted ischemic
) (E) and hMtCd+/SM α-actin + perimeter (length) (F) in ischemic
averaged. HPF, high power field (200×). (G) Double fluorescent
ated CD34+ cells in ischemic hindlimb tissue. Human CD34+ cells
red and the VEGF-A expression was shown in green. Arrowheads
ositive cells for hMtCd and VEGF-A.
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174 K. Kanaya et al.in cultured CD34+ cells (Fig. 2A) in the transplanted SHh-
treated cells in ischemic tissue. Fluorescent double immuno-
staining clearly indicated that transplanted SHh-treated CD34+
cells (hMtCd+ cells) expressed VEGF-A while the transplanted
non-treated CD34+ cells faintly expressed it in ischemic tissue
(Fig. 7G).
These findings suggest that SHh promoted the effect of
CD34+ cells on not only neovascularization with angiogenesis
but also vasculogenesis/arteriogenesis via differentiation
into vascular lineages producing VEGF-A protein in ischemic
tissue.Discussion
Originally, human bone marrow-derived CD34+ cells were
defined as hematopoietic stem/progenitor-rich cells, while
endothelial progenitor cells (EPCs), which play an important
role in post-natal angiogenesis/vasculogenesis in ischemic
tissues, have also been shown to be associatedwith CD34+ cells
(Asahara et al., 1997). CD34+ cells in the human peripheral
blood have recently been used as a tool for therapeutic
angiogenesis of ischemic diseases, with several lines of
evidence accumulated in clinical/animal studies underlining
the therapeutic efficacy of CD34+ cell transplantation. Howev-
er, some previous reports described that the preferential
mechanism of CD34+ cell action is likely an indirect contribu-
tion to angiogenesis, namely, a paracrine effect by production
of a variety of cytokines and angiogenic growth factors rather
than a direct contribution of these cells to angiogenesis/
vasculogenesis in ischemic tissues (Wang et al., 2010). In this
study, we assessedwhether human CD34+ cells could commit to
the vascular lineage upon activation of SHh signaling, and have
demonstrated that 1) Hedgehog signaling was activated by SHh
stimulation in G-CSF mobilized- (Gm-) CD34+ cells, 2) SHh
promoted the functional activity of Gm-CD34+ cells including
their paracrine effects, 3) SHh promoted Gm-CD34+ cell
commitment to vascular lineage, exhibiting a vasculogenic
activity both in vitro and in vivo, and 4) TGFβ signaling pathway
might be involved in the SHh-induced vascular differentiation
of Gm-CD34+ cells.
Pola et al. discovered that SHh triggered neovascularization
through SHh/PTCH signaling as an indirect angiogenic agent
specifically present in mesenchymal cells i.e. fibroblasts for
the first time (Pola et al., 2001), and that the inhibition of SHh
signaling was sufficient to decrease ischemia-induced local
angiogenesis and upregulate VEGF in skeletal fibroblasts (Pola
et al., 2003). Also, Renault et al. reported that SHh does not
activate Gli-dependent transcription in ECs because of the
absence of enhanced PTCHmRNA expression in SHh treated ECs
(Renault et al., 2010). A notable finding of this study is that
human CD34+ cells do indeed express a receptor for SHh, PTCH,
and that the response to SHh protein was also confirmed by
upregulation of mRNA expression of not only the downstream
molecule Gli1 but also SHh and SMO, suggesting that SHh
induced and activated the SHh signaling pathway in G-CSF
stimulated CD34+ cells but not non-stimulated CD34+ cells
via an autocrine mechanism. The angiogenic growth factor
gene and vascular gene expressions are relatively low in
non-mobilized CD34+ cells compared with G-CSF mobilized
CD34+ cells, and the response to SHh treatment was small
except for VEGF-A and eNOS. A possible reason for the smallresponse to SHh in CD34+ cells is due to the short time (24 h)
treatment with SHh in vitro, while the transplanted SHh-
treated CD34+ cells exhibited pro-angiogenic effect, perhaps,
with long term exposure to endogenous SHh production in
ischemic tissue, or only a small subpopulation of CD34+ cells
might be endothelial lineage.
Based on the evidence that SHh is one of the notochord-
derived morphogens which plays a crucial role during
embryonic vascular development (Carmeliet and Tessier-
Lavigne, 2005) and has also been shown to be involved in
postnatal neovascularization, we hypothesized that the SHh
signaling pathway might promote Gm-CD34+ cell function
and increase differentiation into the vascular lineages. To
explore the direct effects of SHh on Gm-CD34+ cells, we
performed a series of experiments in vitro and in vivo. In
contrast to recent studies in which there are no direct effects of
SHh on cellular responses, such as proliferation, migration, and
serum deprived survival, in cultured ECs (Kanda et al., 2003;
Pola et al., 2001), we could demonstrate a direct effect of SHh
on GM-CD34+ cell functions including an increase in prolifera-
tion, adhesion, migration, tube formation, and an upregulation
of SHh signaling-related genes. We further confirmed the
SHh-induced differentiation potential of GM-CD34+ cells into
ECs and VSMCs with marker expressions of eNOS/CD31 and
calponin/SMα-actin, respectively. In hematopoietic stem cells
(HSCs) including CD34+ cells, it has been reported that Notch
and Wnt signaling played a role in the self-renewal and Smad
signaling with TGFβ negatively regulated the growth while
Smad signaling with bone morphogen (BMPs) regulated the
development (Blank et al., 2008). We therefore focused on
these signaling to explore underlying mechanism for SHh-
induced vascular differentiation of Gm-CD34+ cells. Apart from
critical signaling pathway in HSCs, TGFβ-Smad signaling
pathway was highly activated and SHh (1.0 μg/mL) pre-
treatment further upregulated the signaling synchronized with
a variety of vascular transcription factor gene expressions.
Organ including vascular network development is regulated
by differential SHh concentration (Scherz et al., 2007).
Although it would be difficult to translate the in vitro
concentration of SHh to in vivo settings, we assumed that
1.0 μg/mL of SHh would be critical in the contribution of
endogenous CD34+ cells to vascular development or post-
neonatal angiogenesis. Also, SHh-induced TGFβ1 in CD34+
cells might directly promote angiogenesis (Ferrari et al.,
2009) and arteriogenesis (van Royen et al., 2002) influenc-
ing resident ECs and VSMCs in ischemic tissue. On the other
hand, BMP-Smad signaling pathway was downregulated
(Fig. 5) and Notch/Wnt signaling pathway was not affected
(data not shown) by SHh (1.0 μg/mL) pre-treatment in
CD34+ cells.
For in vivo experiments, we utilized transplantation of SHh-
pretreated Gm-CD34+ cells rather than the co-administration of
Gm-CD34+ cells (EPCs) and SHh protein or SHh gene transfer
(Palladino et al., 2012) into ischemic hindlimbs, and could
detect both EC marker and VSMC marker expressing cells,
possibly derived from transplanted Gm-CD34+ cells in the
microvasculature sprouting toward the center of healing during
histological analysis. This morphogenetic effect of transplanted
Gm-CD34+ cells was likely attributed to their direct contribution
to vasculogenesis/arteriogenesis (Supplemental Fig. 4S, left
side) as well as an indirect paracrine effect via secreted
pro-angiogenic growth factors/cytokines from the Gm-CD34+
175Vasculogenic CD34+ cells with Sonic Hedgehogcells activated by SHh (Supplemental Fig. 4S, right side).
Therefore, even though the number of transplanted Gm-CD34+
cells (105 per hindlimb) was lower than that in previous reports
(Madeddu et al., 2004; O et al., 2011; Zhou et al., 2007), the
pre-treatment of Gm-CD34+ cells with SHh could exhibit
immediate paracrine effect at the time of transplantation and
direct contribution to neovascularization differentiating into
ECs and SMCs by endogenous SHh protein production from
ischemic tissue in late phase, resulting in sufficient outcome
compared with non-treated Gm-CD34+ cells. Although SHh
expression in normal adult organs/tissues is extremely limited,
it is expressed constitutively in perivascular and interstitial
tissues, and induced incidentally in ischemic tissues (Kusano et
al., 2005; Pola et al., 2003). This indicates that constitutive or
inducible SHh expression may play a key role during cell fate
decision and functional regulation of circulating CD34+ cells
(EPCs) in situ. As recent papers demonstrated, resident vascular
progenitors are located in adventitia tissues and can contribute
to vascular repair or remodeling by promoting a vasculogenic
zone in the adventitia (Ergun et al., 2011). The induced SHh
expression in the perivascular area could encourage the
recruitment of circulating CD34+ cells, which in turn could
increase their vasculogenic capacity and enhance vascular
repair by the local enrichment of growth factors, and an
increase in the paracrine effect on resident ECs (Supplemental
Fig. 5S, right side). The adventitia as a putative source for SHh
could thus foreordain CD34+ cells into an endothelial phenotype
while promoting the smooth muscle phenotype in the outer
vascular tissue leading to neovascularization (Supplemental Fig.
5S, left side).Conclusions
SHh signaling was activated only in human G-CSF mobilized
(Gm-) CD34+ cells but not in normal CD34+ cells and the
trend appeared to be evident in the patient's Gm-CD34+
cells. The SHh signaling activation enhanced certain cell
functions that are essential for neovascularization includ-
ing vasculogenesis/arteriogenesis demonstrating an in-
creased differentiation potential of these cells into ECs/
VSMCs, with the activated CD34+ cells contributing to
vascular regeneration in ischemic tissues. Since Gm-CD34+
cells with activated SHh signaling are used in ongoing
clinical trials of autologous CD34+ cell transplantation
therapy for non-option patients with ischemic cardiomyop-
athy (Losordo et al., 2011), critical limb ischemia including
Burger disease and ASO (Kawamoto et al., 2009; Kudo et
al., 2003), the modification/pre-treatment of Gm-CD34+
cells with SHh may make sense and therefore enhance the
therapeutic outcome. In terms of inducing stable vascular
regeneration in ischemic tissues, not only angiogenesis with
just ECs but also arteriogenesis with both ECs and pericytes
would be critical aspects of a successful Gm-CD34+ cell
transplantation. Thus, an efficient direct induction system
for human Gm-CD34+ cell differentiation into ECs and
pericytes/VSMCs would be required in Gm-CD34+ cell
transplantation for ischemic diseases. Although further
pre-clinical studies will be warranted, our findings may
give rise to a novel and simple strategy for the next
generation-CD34+ cell therapy in patients with ischemic
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